PRESS CENTER
新聞中心
News
-
2022/09/21Mycenax signs MoU with KriSan Biotech: Building ADC Industry Value Chain
-
2022/07/28JCR Pharmaceuticals invests in Mycenax Biotech, becomes largest shareholder
-
2022/05/30Mycenax re-elected Dr. Allen Y. Chao as independent director
-
2022/01/18Grand Opening Ceremony of Mycenax’s New GMP Manufacturing Plant, Zhunan Science Park
-
2021/08/26Mycenax Reports 2022 H1 EPS of NT$0.32 with business expansion from traditional biologics to allogeneic cell therapy and emerging biologics.
-
2021/08/26Mycenax and Cytiva Enable First Continuous Manufacturing Process Development Satellite Laboratory in Taiwan
-
2021/06/08Mycenax signs an MOU with CHO PHARMA, cooperating to expand the production and application of next-generation antibodies
-
2021/05/28Mycenax becomes Taiwan’s first CDMO company to complete the CHO-S and CHOZN® GS Cell Line Development with the Beacon® Optofluidic System
-
2020/04/30Mycenax Announces the Sale of LusiNEX to Gedeon Richter
-
2020/02/20Mycenax signs agreement with Hummingbird Bioscience for production of anti-vista antibody HMBD-002 for cancer clinical trial.
- 1
- 2
- 3